Cerebral amyloid angiopathy

3 trials 1 recruiting MedDRA PT
3 Registered trials
1 Recruiting
2 Unique sponsors
2 Unique IMPs
3 Commercial trials
Drug classes (ATC)
— ATC code not specified 1
R Respiratory (ATC R) 2
Mechanism of action (INN-stem analysis)
Unknown / small molecule 2 substances
Phase II: 3

Filter these 3 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 3 trials

Phase II

3 trials
  • Alnylam Pharmaceuticals Inc. Commercial
    ALN-961583
    2023-510137-29-01 1 country 2025 n=50
    Recruiting
  • Arctic Therapeutics ehf. Commercial
    ACETYLCYSTEINE AMIDE
    2023-503969-36-00 1 country n=25
    Not authorised
  • Arctic Therapeutics ehf. Commercial
    ACETYLCYSTEINE AMIDE
    2023-503969-36-01 1 country 2024 n=25
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Arctic Therapeutics ehf. Commercial 2 Phase II 0
Alnylam Pharmaceuticals Inc. Commercial 1 Phase II 1
New trials by year
2024
1
2025
1
← All indication landscapes